Whilst TNF inhibitors have generally been shown to be cost-effective in the treatment of RA [18–26], data regarding the relative cost-effectiveness of the various TNF inhibitors are limited and there are few published economic evaluations for certolizumab pegol. The gene discussed is TNF; the disease is rheumatoid arthritis.